H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...

H.C. Wainwright initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $10 price target Perspective is a clinical-stage ...

H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $29 from $30 and keeps a Buy rating on the shares following the Q4 report.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on ...

Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16 ...

Shares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

Ten companies across mixed sectors also mirrored a broader market optimism, booking modest gains during the end of the ...

H.C. Wainwright analyst Amit Dayal initiated coverage on Surf Air Mobility Inc. (NYSE:SRFM) with a Buy rating and price forecast of $12. The analyst writes that the company is positioned for a ...

Tuesday, Summit Therapeutics plc (NASDAQ:SMMT), currently trading at $18.84, maintained a Buy rating from H.C. Wainwright, with analysts keeping a steadfast $44.00 price target on the stock.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com. IN8bio is a clinical-stage ...